Research programme: cell signalling cancer therapeutics - Echelon Biosciences
Latest Information Update: 16 Jan 2008
At a glance
- Originator Echelon Biosciences; University of Texas M. D. Anderson Cancer Center
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Jan 2005 Echelon Biosciences has been acquired by AEterna Zentaris
- 22 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)